Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II-b of naronapride in proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease

Next Previous
Search
Trial Profile

Phase II-b of naronapride in proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naronapride (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Aug 2024 According to a Renexxion media release, Phase 2b study of naronapride in PPI-non-responsive symptomatic GERD is expected to commence in the next 12 months following the recent receipt of a May Proceed Letter and IND clearance from the FDA.
    • 24 Jan 2024 According to a Renexxion media release, company announced U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application of naronapride for the treatment of patients with proton-pump inhibitor (PPI) non-responsive symptomatic gastroesophageal reflux disease (GERD) (PPI-nrsGERD).
    • 24 Jan 2024 According to a Renexxion media release, company expect to begin enrolling patients at sites in the U.S. in a Phase 2b clinical study later this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top